Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 6:07 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,039 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Cancer of the Breast Clear all

Conditions: Fibrosis
Interventions: Pentoxifylline, Vitamin E; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 20 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2012
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Metastatic Breast Cancer, Central Nervous System (CNS) Metastases
Interventions: Lapatinib in Tandem With Capecitabine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 9
States / cities: Ann Arbor, Michigan • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more

Conditions: Healthy Adults
Interventions: Adagrasib, Eltrombopag + adagrasib; Drug
Lead sponsor: Mirati Therapeutics Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Breast Cancer
Interventions: Comprehensive Health Enhancement Support System (CHESS.); Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Female only
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Metastatic Breast Cancer
Interventions: Walk with Ease; Behavioral
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 21 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Breast Cancer
Interventions: Fast MRI; Diagnostic Test
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 21 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms
Interventions: sigvotatug vedotin, pembrolizumab, cisplatin, carboplatin; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 106
States / cities: Anchorage, Alaska • Fayetteville, Arkansas • Rogers, Arkansas + 61 more

Conditions: Breast Cancer, Healthy, no Evidence of Disease
Interventions: soy isoflavones; Dietary Supplement
Lead sponsor: University of Hawaii Cancer Research Center; Other
Eligibility: 30 Years to 45 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Breast Carcinoma, Estrogen Receptor Positive
Interventions: Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Magnetic Resonance Imaging, Positron Emission Tomography, Investigational software and coils in PET/MR scan; Drug · Procedure · Device
Lead sponsor: Andrei Iagaru; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Bladder Carcinoma, Breast Carcinoma, Colorectal Carcinoma, Esophageal Carcinoma, Gastric Carcinoma, Liver Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Ovarian Carcinoma, Pancreatic Carcinoma, Prostate Carcinoma
Interventions: Biospecimen Collection, Device Usage, Electronic Health Record Review, Multi-Cancer Early Detection Test, Questionnaire Administration; Procedure · Device · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 45 Years to 75 Years
Enrollment: 24,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 46
States / cities: Pleasanton, California • San Diego, California • Cheyenne Wells, Colorado + 38 more

Conditions: Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
Interventions: palonosetron hydrochloride, cyclophosphamide, dexamethasone, doxorubicin hydrochloride, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications, ondansetron hydrochloride, survey administration; Drug · Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Distress, Breast Neoplasms, Quality of Life
Interventions: Improvisational Comedy; Behavioral
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer, Ductal Carcinoma, Invasive Breast Carcinoma, Invasive Ductal Breast Carcinoma
Interventions: Talimogene laherparepvec, Paclitaxel; Biological · Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Bilateral Breast Carcinoma, HER2/Neu Negative, Invasive Breast Carcinoma
Interventions: Best Practice, Ixabepilone; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2026
U.S. locations: 3
States / cities: Oak Lawn, Illinois • Houston, Texas

Conditions: Breast Cancer
Interventions: bevacizumab, pegfilgrastim, cyclophosphamide, doxorubicin hydrochloride, paclitaxel albumin-stabilized nanoparticle formulation; Biological · Drug
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older · Female only
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 365
States / cities: Mobile, Alabama • Little Rock, Arkansas • Berkeley, California + 260 more

Conditions: Breast Cancer
Interventions: RAD001, Carboplatin; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Breast Reconstruction, Cosmesis
Interventions: Nipple Sparing Mastectomy; Procedure
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Breast Cancer Female, Breast Cancer, Male, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III, Residual Disease, HER2-positive Breast Cancer, HER2 Positive Breast Carcinoma
Interventions: DC1 Vaccine, WOKVAC Vaccine; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 7
States / cities: Tampa, Florida • Atlanta, Georgia • Indianapolis, Indiana + 4 more

Conditions: Breast Cancer
Interventions: Questionnaires and Focus Group; Other
Lead sponsor: University of Central Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Breast Cancer
Interventions: Gemcitabine, Trastuzumab, Pertuzumab; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions: Aprepitant, Cyclophosphamide, Dexamethasone, Granisetron hydrochloride; Drug
Lead sponsor: Barbara Ann Karmanos Cancer Institute; Other
Eligibility: 18 Years to 120 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: HER2-positive Breast Cancer
Interventions: tucatinib, placebo, T-DM1; Drug
Lead sponsor: Seagen, a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 466 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 321
States / cities: Mobile, Alabama • Gilbert, Arizona • Goodyear, Arizona + 180 more

Conditions: Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Triple-Negative Breast Carcinoma
Interventions: Biopsy Procedure, Biospecimen Collection, Cediranib Maleate, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Olaparib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2027
U.S. locations: 14
States / cities: Los Angeles, California • Chicago, Illinois • Evanston, Illinois + 8 more

Conditions: Breast Cancer
Interventions: Diagnostic Breast Cancer Scan, Research Scan for Gradient-echo Spectroscopic Imaging (GSI); Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 25 Years to 99 Years · Female only
Enrollment: 190 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2026
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Trental & Vitamin E for Radiation-Induced Fibrosis

Intermittent High-Dose Lapatinib in Tandem With Capecitabine for HER2 Overexpressed/Amplified Metastatic Breast Cancer With Central Nervous System (CNS) Metastases

A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib

Moderating the Negative Impact of Abnormal Screening Mammograms

Physical Activity to Maintain Quality of Life and Physical Function in Women With Metastatic Breast Cancer: a Pilot Study

Community Hospital Identification of High CV Risk Patients During Cancer Treatment

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Effect of Dietary Soy on Estrogens in Breast Fluid, Blood, and Urine Samples From Healthy Women

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

The Vanguard Study: Testing a New Way to Screen for Cancer

Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer

LOL: It's All Improv After Cancer! The Impact of Improvisational Comedy on Well-Being Among Patients With Cancer

Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

RAD001 Plus Carboplatin in Breast Cancer Patients

Nipple Sparing Mastectomy - Cosmetic Outcomes

Vaccine to Prevent Recurrence in Patients With HER-2 Positive Breast Cancer

MammoVerse: Breast Cancer Sexual Health Focus Groups

Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer